There are 2949 resources available
LBA86 - Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN
Presenter: Jonathan Goldman
Session: Mini Oral - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
1781MO - IMpower133: Characterisation of long-term survivors treated first-line with chemotherapy ± atezolizumab in extensive-stage small cell lung cancer
Presenter: Stephen Liu
Session: Mini Oral - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
1782MO - Health-related quality of life (HRQoL) in KEYNOTE-604: Pembrolizumab (pembro) or placebo added to etoposide and platinum (EP) as first-line therapy for ES-SCLC
Presenter: Hye Ryun Kim
Session: Mini Oral - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
1895MO - Three-year follow-up results of the MERIT trial: A Japanese phase II study of nivolumab in malignant pleural mesothelioma
Presenter: Hidetoshi Hayashi
Session: Mini Oral - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
1896MO - Volumetric PET response assessment outperforms conventional criteria in patients receiving high-dose pembrolizumab for malignant mesothelioma
Presenter: Daniel C. Christoph
Session: Mini Oral - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
LBA49 - Durvalumab after chemoradiotherapy in stage III NSCLC: 4-year survival update from the phase III PACIFIC trial
Presenter: Corinne Faivre-Finn
Session: Mini Oral - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
1081MO - Efficacy of ipilimumab plus nivolumab or ipilimumab plus fotemustine vs fotemustine in patients with melanoma metastatic to the brain: Primary analysis of the phase III NIBIT-M2 trial
Presenter: Anna Di Giacomo
Session: Mini Oral - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
LBA48 - Clinical efficacy and immunity of combination therapy with nivolumab and IDO/PD-L1 peptide vaccine in patients with metastatic melanoma: A phase I/II trial
Presenter: Inge-Marie Svane
Session: Mini Oral - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
1082MO - 5-year characterization of complete responses in patients with advanced melanoma who received nivolumab plus ipilimumab (NIVO+IPI) or NIVO alone
Presenter: Caroline Robert
Session: Mini Oral - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
1158MO - Metabolomic profile of advanced neuroendocrine cancer patients
Presenter: Beatriz Soldevilla
Session: Mini Oral - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast